Clinical trial NCT03258359: Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)
Official title: A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens (PACTN) in Patients With Myelodysplastic Syndromes (MDS)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Myelodysplastic Syndromes
Keywords: MDS
Lead sponsor: PersImmune, Inc
Sponsor class: INDUSTRY
Collaborators: name: University of California, San Diego
First posted: 2017-08-23
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety of autologous T cells that have been immunized ex vivo with patient-specific MDS stem cell neoantigens in patients with MDS.

Detailed description: PACTN is manufactured by a novel method to employ cancer-specific somatic variants (mutations) as a means to immunize autologous T lymphocytes to specifically kill cancer cells bearing the protein products of the mutations.

The PACTN method is based on the premise that somatic DNA mutations that cause cancer often give rise to proteins with an altered amino acid sequence. Peptides derived from these proteins, if expressed in the context of MHC Class I or II may be perceived as "non-self" by the immune system; that is, they may be perceived as neoantigens (aka, neoepitopes). Such neoantigens could therefore serve as immunogenic targets for the development of patient-specific, personalized T cell mediated immunotherapy.

Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of MDS according to the French-American-British (FAB) criteria. Subjects with MDS must have intermediate, high, or very high risk IPSS-R scores and cytopenia of at least one lineage.
* Relapsed/refractory disease, or inadequate response to at least 6 cycles of hypomethylating (HMA) therapy or subjects who decline HMA therapy. Subjects must not have received any MDS or AML directed therapy for \>28 days prior to receiving the study treatment.
* Subjects who have opted not to undergo allogeneic hematopoietic stem cell transplantation or for whom no donor is available and who are not deemed eligible for high intensity chemotherapy.
* Age \>18 year at the time of obtaining informed consent, male or female.
* An Eastern Cooperative Oncology Grou (ECOG) performance status score of 0, 1, or 2.
* Adequate organ function.
* Seronegative test for HIV-1/2 and hepatitis C antibodies (HCV), and a negative test for Hepatitis B antigen (HBsAg). If hepatitis C antibody test is positive, then the subject must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
* Women of childbearing potential must have negative pregnancy test prior to initiating study treatment.
* Life expectancy \>6 months at time of screening.
* Ability to adhere to the protocol requirements and study visit schedule.

Exclusion Criteria:

* Subjects who anticipate use of other investigational or non-investigational agents for the treatment of MDS during the study period, aside from a stable dose of erythropoietin stimulating agent started \>8 weeks prior to screening for this study.
* Subjects who have received investigational agents, cytotoxic chemotherapy, or radiotherapy within 28 days prior to entering the study, or who have not recovered from AEs dur to agents administered more than 28 days earlier.
* Subjects who are less than 21 days from surgery or have insufficient recovery from surgical-related trauma or wound healing.
* Prior history of allogeneic hematopoietic stem cell transplantation.
* Current use of granulocyte colony-stimulating factory (G-CSF) or GM-CSF.
* History of major organ autoimmune disease.
* Concurrent immunosuppressive therapy. A stable dose of prednisone \<10 mg daily or inhaled corticosteroids are allowed.
* Any form of primary immunodeficiency.
* Active bacillus tuberculosis (TB) or any other active or uncontrolled infection.
* Pior history of treated malignancy in the past 2 years. Subjects with non-melanoma skin cancer, localized prostate cancer, and carcinoma in situ of the breast of cervix are allowed.
* Impaired cardiac function.
* Pregnant women are excluded from this study as the proposed treatment has not been well studied in pregnant subjects.
* Any other medical or psychiatric disorders, or social situation, that would, in the investigator's opinion, place the subject at unacceptable risk if he/she participates in the study.

Primary outcomes:
measure: Acute and subacute toxicities and AEs
timeFrame: baseline to four weeks after infusion
Secondary outcomes:
measure: Persistence, abundance, and activity of PACTN
timeFrame: Samples will be collected on days 1, 4, 8, 15, 36, and 57, and then 3, 6, and 12 months
measure: Disease Response
timeFrame: Samples will be collected between day 29 and 43, and then at 3, 6, and 12 months
measure: Overall and progression-free survival of subjects who receive PACTN
timeFrame: Six and 12 months after PACTN infusion
Other outcomes:
measure: The duration of hematologic response, if any
timeFrame: Up to 12 months
measure: PACTN persistence or peak abundance and clinical response
timeFrame: 6 months and 1 year
measure: Changes in Variant allele frequency (VAF) of somatic mutations targeted by PACTN
timeFrame: From 4 days up to 1 year
Locations:
city: San Diego
country: United States
facility: University of California, San Diego
state: California
Study officials:
affiliation: PersImmune, Inc
name: Antonella Vitiello, PhD
role: STUDY_DIRECTOR
References: